NO20044825L - Cystein proteaseinhibitor - Google Patents

Cystein proteaseinhibitor

Info

Publication number
NO20044825L
NO20044825L NO20044825A NO20044825A NO20044825L NO 20044825 L NO20044825 L NO 20044825L NO 20044825 A NO20044825 A NO 20044825A NO 20044825 A NO20044825 A NO 20044825A NO 20044825 L NO20044825 L NO 20044825L
Authority
NO
Norway
Prior art keywords
cysteine protease
protease inhibitor
lactoferrin
inhibitor
transferrin
Prior art date
Application number
NO20044825A
Other languages
English (en)
Inventor
Nobuhiko Katunuma
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Publication of NO20044825L publication Critical patent/NO20044825L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)

Abstract

Denne oppfinnelsen vedrører en inhibitor av cystein-protease omfattende en eller flere laktoferriner, peptidfragmenter av laktoferrin og transferriner som aktiv ingrediens. Inhibitoren av cystein-protease i henhold til den foreliggende oppfinnelse kan anvendes som forebyggende eller terapeutisk legemiddel for osteoporose, ondartet hyperkalsemi, osv., og brukes som mat, drikke, fôr og lignende.
NO20044825A 2002-11-29 2004-11-05 Cystein proteaseinhibitor NO20044825L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002347802 2002-11-29
PCT/JP2003/015007 WO2004050116A1 (ja) 2002-11-29 2003-11-25 プロテアーゼ阻害剤

Publications (1)

Publication Number Publication Date
NO20044825L true NO20044825L (no) 2005-01-25

Family

ID=32462896

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044825A NO20044825L (no) 2002-11-29 2004-11-05 Cystein proteaseinhibitor

Country Status (10)

Country Link
US (1) US20050176123A1 (no)
EP (1) EP1576964A4 (no)
JP (2) JP3726095B2 (no)
KR (1) KR100700316B1 (no)
CN (1) CN100379448C (no)
AU (1) AU2003284441A1 (no)
CA (1) CA2485957A1 (no)
NO (1) NO20044825L (no)
NZ (1) NZ536338A (no)
WO (1) WO2004050116A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2875501B1 (fr) * 2004-09-21 2008-02-29 Univ Paris Descartes Nouveaux derives peptidiques, compositions et utilisations dans un traitement therapeutique de l'infection par un herpesvirus
US7956031B2 (en) * 2005-05-31 2011-06-07 Naidu Lp Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy
AU2006300009A1 (en) * 2005-10-14 2007-04-19 Auckland Uniservices Limited Use of lactoferrin fragments and hydrolysates
US8021659B2 (en) * 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US20110038917A1 (en) * 2007-05-08 2011-02-17 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
JP2010180219A (ja) * 2010-03-04 2010-08-19 Snow Brand Milk Prod Co Ltd ラクトフェリン組成物
JP2013079216A (ja) * 2011-10-04 2013-05-02 Snow Brand Milk Products Co Ltd 感覚改善剤
US20160089400A1 (en) 2013-04-08 2016-03-31 N.V. Nutricia Fermented nutritional composition with thiol protease inhibitor
CN112351791A (zh) * 2018-06-26 2021-02-09 S&K生物制药有限公司 糖胺聚糖抑制剂和促进剂
CN111528269B (zh) * 2020-05-21 2022-11-25 南通大学 一种肉制品蛋白保鲜防腐剂及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2029192A (en) * 1991-05-31 1993-01-08 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Human lactoferrin
DK0559425T3 (da) * 1992-03-02 1999-08-30 Japan Immuno Inc Anvendelse af proteiner tilhørende transferrin/lactoferrinfamilien til stimulering af immunsystemet
JP3100005B2 (ja) * 1992-07-28 2000-10-16 雪印乳業株式会社 ヒト免疫不全ウィルス感染・増殖抑制剤
JP3112637B2 (ja) * 1994-09-30 2000-11-27 雪印乳業株式会社 骨強化剤
JP3613488B2 (ja) * 1996-01-17 2005-01-26 雪印乳業株式会社 栄養補給用組成物
ATE258229T1 (de) * 1996-02-21 2004-02-15 Taiho Pharmaceutical Co Ltd Substanz fa-70d, herstellungsverfahren und verwendungen
JPH1080281A (ja) * 1996-09-06 1998-03-31 Snow Brand Milk Prod Co Ltd 新規蛋白質及びその製造方法
JPH11292789A (ja) * 1998-04-03 1999-10-26 Meiji Milk Prod Co Ltd 病原性大腸菌の細胞への付着阻害組成物
JP4592127B2 (ja) * 1999-03-30 2010-12-01 雪印乳業株式会社 骨吸収抑制剤
JP3739589B2 (ja) * 1999-03-31 2006-01-25 雪印乳業株式会社 骨強化剤
US6649590B2 (en) * 2000-06-09 2003-11-18 Snow Brand Milk Products Co., Ltd. Method of producing fractions containing a high concentration of milk basic cystatin and decomposition products thereof
JP2002281586A (ja) * 2001-03-16 2002-09-27 Kenwood Corp 音響再生装置
WO2002077239A1 (fr) * 2001-03-27 2002-10-03 Sumitomo Pharmaceuticals Company, Limited Polypeptides se liant au virus hcv
CN1166688C (zh) * 2002-03-13 2004-09-15 徐跃 一种从乳清液中分离乳铁传递蛋白的方法
US20030191193A1 (en) * 2002-04-03 2003-10-09 Jillian Cornish Lactoferrin

Also Published As

Publication number Publication date
JPWO2004050116A1 (ja) 2006-03-30
KR20050027215A (ko) 2005-03-18
CN100379448C (zh) 2008-04-09
AU2003284441A1 (en) 2004-06-23
JP2005213260A (ja) 2005-08-11
EP1576964A4 (en) 2008-06-11
JP4250599B2 (ja) 2009-04-08
CN1691957A (zh) 2005-11-02
EP1576964A1 (en) 2005-09-21
US20050176123A1 (en) 2005-08-11
KR100700316B1 (ko) 2007-03-29
JP3726095B2 (ja) 2005-12-14
CA2485957A1 (en) 2004-06-17
WO2004050116A1 (ja) 2004-06-17
NZ536338A (en) 2006-04-28

Similar Documents

Publication Publication Date Title
ATE513917T1 (de) Bakterielle expression von proteaseinhibitoren und varianten davon
WO2002076939A3 (en) Cysteine protease inhibitors
HK1070305A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an sg(a)-aminoamide and its analgesic use
MXPA05011784A (es) Producto de caseina hidrolizada que comprende tripeptidos isoleucina-prolina-prolina y/o valina-prolina-prolina.
DK1957061T3 (da) Kombination omfattende mindst én aminosyre og en PKR-inhibitor til anvendelse i behandlingen af muskelsvind
GEP20104974B (en) Carbonylamino pyrrolopyrazoles, protent kinase inhibitors
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
Udenigwe Towards rice bran protein utilization: In silico insight on the role of oryzacystatins in biologically-active peptide production
NO20044825L (no) Cystein proteaseinhibitor
NO20044207L (no) Katepsin som cysteinproteaseinbibitorer
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
JO2596B1 (en) Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
RU2008116176A (ru) Стимулятор секреции глюкагон-подобного пептида 1, продукты питания или напитки, стимулирующие секрецию глюкагон-подобного пептида 1, ингибитор постпрандиальной гипергликемии и продукта питания или напитки, ингибирующие постпрандиальную гипергликемию
NO20063842L (no) Silinanforbindelser som cysteinproteaseinhibitorer
DE50101858D1 (en) Urokinase-hemmstoffe
JO2963B1 (en) Reconstructed surfactants with improved properties
ATE438618T1 (de) Inhibitoren von humanem adam-10
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
MXPA05012675A (es) Compuestos de hidroxiamidina e hidroxiguanidina como inhibidores de urocinasa.
SI1622939T1 (sl) Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega
WO2002096348A3 (fr) Produit comprenant du mikanolide ou du dihydromikanolide en association avec un autre agent anti-cancereux
ATE540971T1 (de) Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
WO2012046945A3 (ko) 당뇨병 또는 비만의 예방 또는 치료용 약학 및 식품 조성물
WO2005063742A3 (en) Amidino compounds as cysteine protease inhibitors
TW200510436A (en) Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application